AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended). An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of stimulating angiogenesis in a tissue, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be directly administered to a tissue to stimulate angiogenesis in said tissue, and wherein said pharmaceutical composition comprises a nucleic acid having a nucleotide sequence capable of expressing an active human Src protein, and wherein the pharmaceutical composition contains a pharmaceutically acceptable carrier or excipient and an amount of said nucleic acid sufficient to ~~deliver at least 0.1 grams of human Src protein per 100 grams of pharmaceutical composition~~ express an angiogenesis stimulating amount of the active human Src protein in said tissue.

Claims 2 and 3 (cancelled).

Claim 4 (previously presented). The article of manufacture of claim 1 wherein said tissue has poor circulation.

Claims 5-13 (canceled).

Claim 14 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition further comprises a liposome.

Claim 15 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition comprises a viral expression vector capable of expressing said nucleotide sequence.

Claim 16 (currently amended): The article of manufacture of claim 1 wherein said pharmaceutical composition comprises [[an]] a non-viral expression vector capable of expressing said nucleotide sequence.

Claims 17-32 (canceled).

Claim 33 (currently amended): A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid and a pharmaceutically acceptable carrier or excipient; said nucleic acid having a

nucleic acid segment encoding for an active src protein having the amino acid residue sequence of SEQ ID NO: 5, wherein the pharmaceutical composition contains an amount of said nucleic acid sufficient to ~~deliver at least 0.1 grams of the active src protein per 100 grams of pharmaceutical composition~~ express an angiogenesis stimulating amount of the active src protein in said tissue.

Claim 34 (currently amended): A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for an active src protein having the amino acid residue sequence of SEQ ID NO: 5, wherein the pharmaceutical composition contains an amount of said nucleic acid sufficient to ~~deliver at least 0.1 grams of the active src protein per 100 grams of pharmaceutical composition~~ express an angiogenesis stimulating amount of the active src protein in said tissue.

Claims 35-38 (canceled).